AL-S PHARMA
AL-S Pharma AG develops AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of ALS.
AL-S PHARMA
Industry:
Health Care Medical
Founded:
2016-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Total Employee:
1+
Status:
Active
Similar Organizations
Cellective BioTherapy
Cellective BioTherapy develops novel cellular and monoclonal antibody-based platforms to treat cancer, autoimmunity, and immunodeficiency.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Investors List
Neurimmune Holding
Neurimmune Holding investment in Seed Round - AL-S Pharma
TVM Capital Life Science
TVM Capital Life Science investment in Seed Round - AL-S Pharma
More informations about "AL-S Pharma"
AL-S Pharma - Crunchbase Company Profile & Funding
Organization. AL-S Pharma . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. About. AL-S Pharma AG develops AP-101, a human monoclonal …See details»
AL-S Pharma 2025 Company Profile: Valuation, …
Jan 1, 2016 AL-S Pharma was founded in 2016. Where is AL-S Pharma headquartered? AL-S Pharma is headquartered in Zurich, Switzerland. What industry is AL-S Pharma in? AL-S Pharma’s primary industry is Drug …See details»
Pipeline – Neurimmune
AP-101 is a human antibody directed against misfolded superoxide dismutase 1 (SOD1). Currently, safety, tolerability, pharmacokinetics and pharmacodynamics of AP-101 are assessed in patients with ALS. Neurimmune and TVM Capital …See details»
Neurimmune and TVM Capital Life Science Announce the …
Nov 18, 2021 AL-S Pharma AG, a biotech company jointly founded by Neurimmune and TVM Capital Life Science, announced today enrollment of the first patient in a multicenter, placebo …See details»
AL-S Pharma AG - startup.ch
AL-S Pharma AG: AL-S Pharma AG is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TTVM Life Science Innovation I L.P. and Neurimmune. AL-S Pharma plans to begin …See details»
AL-S Pharma AG - TVM Capital Life Science Venture Capital
AL-S Pharma AG is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TVM Life Science Innovation I L.P. and Neurimmune. …See details»
AL-S Pharma - Headquarter Location, Corporate Office Address …
AL-S Pharma is Drug Discovery in Switzerland that focus on developer business. Founded in 2016. They cover business area such as developer, therapeutic benefit, patient, amyotrophic …See details»
AL-S Pharma AG Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for AL-S Pharma AG of Schlieren, ZÜRICH. Get the latest business insights from Dun & Bradstreet.See details»
AL-S Pharma AG - Drug pipelines, Patents, Clinical trials - Patsnap
Explore AL-S Pharma AG with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 4 news, and 1 literature, Disease Domain:Endocrinology and Metabolic Disease, …See details»
Initiation of AL-S Pharma’s phase 2 study for ... - Swiss Biotech
Nov 18, 2021 AP-101 is a human antibody directed against misfolded superoxide dismutase 1 (SOD1). “We are excited to initiate Phase 2 clinical development of AP-101 and hope to …See details»
Companies Create AL-S Pharma to Develop Novel ALS …
Dec 8, 2016 AL-S Pharma is aiming to to launch its first study of AP-101 in humans in 2018, working with an international network of ALS clinics. Salzmann will oversee the development of AP-101. “Neurodegeneration is a core …See details»
AP-101 by AL-S Pharma for Amyotrophic Lateral Sclerosis: …
Dec 4, 2024 AL-S Pharma overview. AL-S Pharma, is a developer of a human monoclonal antibody solutions. The company is headquartered in Switzerland. For a complete picture of …See details»
Neurimmune and TVM Capital Life Science Announce Creation of …
Jul 12, 2016 AL-S Pharma AG is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TVM Life Science Ventures VII and …See details»
American Association of Pharmaceutical Scientists - AAPS
The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 10,000 members employed in academia, industry, government, …See details»
Home - American Association of Pharmaceutical Scientists
The American Association of Pharmaceutical Scientists (AAPS) encourages participation in our meetings and conferences with abstract submissions of your research for poster presentation …See details»
MaaT Pharma Announces Promising Final Data Readout for Phase …
2 days ago MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 [email protected] MaaT Pharma – Media Relations …See details»
AL-S Pharma AG (AL-S Pharma AG) - 药物管线_专利_临床试验_投 …
了解AL-S Pharma AG (AL-S Pharma AG)公司的药物管线，治疗领域，技术平台，以及它的2项临床试验, 4篇新闻和1篇文献，疾病领域:内分泌与代谢疾病，神经系统疾病，技术平台:单克隆 …See details»
Trump Meets Syrian President After Pledge to Lift Sanctions: Live ...
May 4, 2025 President Trump’s meeting with President Ahmed al-Shara capped a remarkable turnabout for the leader of the rebel uprising that ousted Bashar al-Assad. Mr. Trump has said …See details»
Amyotrophic Lateral Sclerosis – Neurimmune
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease marked by the degeneration of motor neurons in the spinal cord and brain resulting in progressing paralysis …See details»
The ALSFRS-R Summit: a global call to action on the use of the …
Feb 23, 2024 Introduction. The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) was developed more than 25 years ago as an instrument to monitor functional …See details»